Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  therapeutic autologous dendritic cells
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 70 for your search:
Start Over
Vaccine Therapy in Treating Patients With Liver Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: NCI, Other
Protocol IDs: CDR0000068806, P30CA016042, UCLA-0001026, NCI-G01-1997, NCT00022334
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: over 18
Sponsor: Other
Protocol IDs: CDR0000270762, ERLANGEN-ONTAK, EU-20246, NCT00056134
Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each Patients' Own Immune Cells.
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: RDA 0466, NCT00289341
Combined Modality Treatment for Patients With Stage IV Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 21 to 75
Sponsor: Other
Protocol IDs: Baylor IRB #006-025-01, IND 12919, NCT00313235
Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: RDA-0537, NCT00345293
Dendritic Cell Based Therapy of Renal Cell Carcinoma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: UR0414, NCT00197860
Dendritic Cell Based Therapy of Malignant Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: MM0413, NCT00197912
Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection
Phase: Phase II, Phase I
Type: Diagnostic, Treatment
Status: Completed
Age: 18 to 75
Sponsor: Other
Protocol IDs: 2004-3126, KUN99-1950, NCT00243594
Preoperative Intratumor Dendritic Cells Injection Immunotherapy for Patients With Pancreatic Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 20 and over
Sponsor: Other
Protocol IDs: 198, NCT00795977
A Study Evaluating Vaccination of Prostate Cancer Patients With Self Dendritic Cells Expressing MUC1
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 19 and over
Sponsor: Other
Protocol IDs: CAN-ONC-001 CAN, NCT00852007
Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma
Phase: Phase II, Phase I
Type: Treatment
Status: Temporarily closed
Age: 19 months to 35 years
Sponsor: NCI
Protocol IDs: 070206, 07-C-0206, NCT00923351
Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 to 70
Sponsor: Other
Protocol IDs: NL22750.000.08, KUN2006-3699, NCT00940004
Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: Over 16
Sponsor: Other
Protocol IDs: CDR0000068481, HOAG-VACCINE-MEL, NCI-V01-1646, NCT00012064
Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSI
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 to 75
Sponsor: Other
Protocol IDs: EudraCT 2008-005584-33, NCT01885702
Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: ERLANGEN-DERMA-ER-DC-06, CDR0000343699, EU-20317, NCT00074230
A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas
Phase: Phase II
Type: Treatment
Status: Completed
Age: 35 and under at initial diagnosis
Sponsor: NCI
Protocol IDs: 970052, 97-C-0052, NCI-97-C-0052, NCI-T96-0038, T96-0038, NCT00019266, NCT00001566
Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: CDR0000067277, NCI-99-C-0132, NCT00019890
p53 Vaccine for Ovarian Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: 990137, 99-C-0137, NCI-99-C-0137, NCI-NMOB-9903, NCI-T99-0074, T99-0074, NCT00019903, NCT00001827
APC8015 and Bevacizumab in Treating Patients With Prostate Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: NCI
Protocol IDs: NCI-2012-02427, UCSF-0155-01, NCI-2617, UCSF-01554, CDR0000069047, 2617, NCT00027599
DC Vaccine Combined With IL-2 and IFNa-2a in Treating Patients With mRCC
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000370794, R01CA095648, P30CA023108, DMS-0238, DMS-16090, NCT00085436
Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: UARK 2000-46, NCT00083538
Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: Pro00007616, DUMC-5883-04-6RO, CDR000041079, 8087, NCT00103142
Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 to 80
Sponsor: NCI, Other
Protocol IDs: CDR0000410830, R21CA091624, UKMC-IRB-0391-F2R, UKMC-CTRF-G-01-009, NCT00103116
Start Over